Short-term efficacy of inhaled short-acting beta-2-agonists for acute wheeze/asthma symptoms in preschool-aged children: a systematic review and meta-analysis.

We examine the efficacy of inhaled SABA for preschool-aged children presenting with acute wheeze/asthma in this systematic reviewand meta-analysis.

在这项系统评价和荟萃分析中，我们检查了吸入性SABA对学龄前儿童急性喘息/哮喘发作的疗效。

Methods

PubMed and Embase were searched through August 2024.

检索了截至2024年8月的PubMed和Embase数据库。

Clinical trials investigating the effect of inhaled SABA on acute wheeze/asthma symptoms in children below age 6 years were included.

纳入了研究吸入性短效β2受体激动剂(SABA)对6岁以下儿童急性喘息/哮喘症状影响的临床试验。

The study followed Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines.

该研究遵循了系统评价和荟萃分析报告的首选条目（PRISMA）指南。

Summary standardised mean differences, 95% CIs and p values were derived from random effects meta-analyses to analyse the effect on clinical composite respiratory score, respiratory rate, oxygen saturation, respiratory work and degree of wheezing.

通过随机效应荟萃分析得出的汇总标准化平均差异、95%置信区间和p值，用于分析对临床综合呼吸评分、呼吸频率、氧饱和度、呼吸工作量和喘息程度的影响。

Results

A total of 19 studies including 1022 children were included.

共有19项研究纳入了1022名儿童。

Treatment with inhaled SABA showed decreased respiratory score within 60 min (10 studies, N=523): standardised mean difference -2.05 points (95% CI -2.50; -1.59), I2=86%, p<0.001, decreased respiratory rate (8 studies, N=319): -0.86 (95% CI -1.30; -0.41), I2=87%, p<0.001, increased oxygen saturation (7 studies, N=190): 0.56 (95% CI 0.16; 0.95), I2=71%, p<0.01, decreased respiratory work (3 studies, N=68): -0.80 (95% CI -1.60; -0.00), I2=74%, p=0.05 and decreased wheezing score (3 studies, N=68): -1.07 (95% CI -1.80; -0.33), I2=72%, p<0.01.

吸入性SABA治疗在60分钟内显示出呼吸评分降低（10项研究，N=523）：标准化平均差异为-2.05分（95%置信区间-2.50至-1.59），I2=86%，p<0.001；呼吸频率降低（8项研究，N=319）：-0.86（95%置信区间-1.30至-0.41），I2=87%，p<0.001；氧饱和度增加（7项研究，N=190）：0.56（95%置信区间0.16至0.95），I2=71%，p<0.01；呼吸努力度降低（3项研究，N=68）：-0.80（95%置信区间-1.60至-0.00），I2=74%，p=0.05；以及喘息评分降低（3项研究，N=68）：-1.07（95%置信区间-1.80至-0.33），I2=72%，p<0.01。

Subgroup analyses of children below age 2 years showed similar significant effects for all outcomes.

对2岁以下儿童的亚组分析显示，所有结果均显示出类似的显著效应。

Conclusions

Inhaled SABA treatment for acute wheeze/asthma symptoms showed beneficial effects in young children and infants.

吸入性短效β2受体激动剂(SABA)治疗急性喘息/哮喘症状，在年幼儿童和婴儿中显示出有益效果。

Findings from this study may provide evidence to support inhaled SABA in future treatment guidelines for acute wheeze/asthma among young children and infants; however, an overall high heterogeneity and small sample size of the studies were a limitation.

本研究的发现可能为未来治疗指南中吸入性短效β2受体激动剂(SABA)在幼儿和婴儿急性喘息/哮喘治疗中的应用提供证据；然而，研究的总体异质性高和样本量小是一个局限性。

prospero_registration_number

CRD42023429381.

CRD42023429381。